Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 0.63 |
| ▸ | ACHE | P22303 | 8/20 | 0.51 |
| ▸ | BCHE | P06276 | 7/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952802 | 0.90 | GSK3B (0.53) | GSK3BACHEBCHE | |
| SCHEMBL954063 | 0.88 | GSK3B (0.66) | GSK3BACHEBCHECDC7DBF4 | |
| SCHEMBL953055 | 0.79 | CDC7 (0.61) | GSK3BACHEBCHECDC7CCNE1 | |
| SCHEMBL955917 | 0.78 | CDC7 (0.69) | GSK3BCDC7DBF4 | |
| SCHEMBL953912 | 0.78 | MAPK14 (0.42) | GSK3BCDC7DBF4 | |
| SCHEMBL623030 | 0.77 | GSK3B (0.56) | GSK3BCDC7DBF4 | |
| SCHEMBL22374870 | 0.77 | GSK3B (1.00) | GSK3BACHEBCHEGSK3ACDK9 | |
| SCHEMBL957562 | 0.75 | CDC7 (0.71) | GSK3BCDC7DBF4 | |
| SCHEMBL23106172 | 0.74 | GSK3B (0.74) | GSK3BACHEBCHEGSK3ACDK9 | |
| SCHEMBL954260 | 0.72 | CDC7 (0.60) | GSK3BCDC7CCNE1CDK2DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | GSK3B 62/4885ACHE 4845/4885BCHE 4624/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | GSK3B 80/4885ACHE 4721/4885BCHE 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.